UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 155 filers reported holding UNIQURE NV in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $84,103 | -38.9% | 12,534 | +4.4% | 0.01% | -44.4% |
Q2 2023 | $137,623 | -31.9% | 12,009 | +100.2% | 0.01% | +80.0% |
Q1 2021 | $202,000 | -6.9% | 6,000 | 0.0% | 0.01% | -16.7% |
Q4 2020 | $217,000 | +119.2% | 6,000 | +122.2% | 0.01% | +20.0% |
Q3 2020 | $99,000 | -24.4% | 2,700 | -6.9% | 0.01% | -28.6% |
Q2 2020 | $131,000 | +13000.0% | 2,900 | +16011.1% | 0.01% | – |
Q4 2019 | $1,000 | -90.0% | 18 | -98.2% | 0.00% | -100.0% |
Q3 2017 | $10,000 | -23.1% | 992 | -56.9% | 0.00% | -50.0% |
Q4 2016 | $13,000 | -61.8% | 2,300 | -48.9% | 0.00% | -50.0% |
Q3 2016 | $34,000 | +126.7% | 4,500 | +114.3% | 0.00% | +100.0% |
Q2 2016 | $15,000 | -58.3% | 2,100 | -30.0% | 0.00% | -60.0% |
Q1 2016 | $36,000 | +80.0% | 3,000 | +150.0% | 0.01% | +66.7% |
Q4 2015 | $20,000 | -51.2% | 1,200 | -40.0% | 0.00% | -50.0% |
Q3 2015 | $41,000 | -56.8% | 2,000 | -42.9% | 0.01% | -53.8% |
Q2 2015 | $95,000 | +21.8% | 3,500 | +9.4% | 0.01% | +18.2% |
Q1 2015 | $78,000 | – | 3,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |